ASPI enters its August 21 earnings print as one of the most heavily shorted small-cap names on Nasdaq, with short sellers adding positions even as the stock falls — a combination that makes the upcoming report unusually high-stakes.
Short interest has climbed to nearly 24% of the free float, up roughly 8% on the week and 10% over the past month. That directional build is the key detail: bears have been actively adding, not covering, through the recent price weakness. The borrow market confirms the conviction on the short side. Availability has tightened to just 2.9% — meaning almost every share in the lending pool is currently committed — matching the most constrained readings of the past year. Despite that tightness, the cost to borrow has collapsed from around 1.7% in early August to under 0.2%, a paradox that suggests lenders are rolling existing borrows cheaply rather than fresh shorts paying up. The ORTEX short score has crept to 74.8, its highest reading in the dataset, ranking ASPI in the first percentile of the universe on both short score and days-to-cover. The stock itself closed at $3.86, down nearly 4% on Monday and off 11% on the week — the share price has roughly halved from the $7–8 range where insiders were selling aggressively in late May and early June.
Options positioning tells a contrasting story. Bulls are clearly more active in the options market than bears. The put/call ratio has dropped to 0.22, well below its 20-day average of 0.26 and near the bottom of its 52-week range. That is almost 1.4 standard deviations light on puts — traders are leaning toward calls, not hedging for downside. The divergence between a historically tight borrow market and a call-heavy options book is the defining tension of this setup.
The bull and bear cases are both coherent, which is what makes this a genuine debate. Bulls point to DOE backing, a partnership with the South African Nuclear Energy Corporation, and a positioning as the sole commercial provider of certain enriched isotopes for nuclear medicine and quantum technology. The 90-day EPS momentum factor ranks in the 82nd percentile, suggesting forward estimates have been moving in the right direction. Coverage from Canaccord Genuity and Cantor Fitzgerald — both maintaining Buy/Overweight ratings with targets of $11–$13 — implies substantial upside from current levels, though the most recent formal action from Canaccord dates to April, when it simply reiterated its stance. Bears counter that ASPI remains a development-stage issuer, with negative earnings, a PE ratio deeply in the red, and meaningful execution risk around scaling production in South Africa. The 90-day insider net selling cluster — the CEO, CFO, General Counsel, and multiple directors all sold in June at $6–8 per share — adds a layer of concern that insiders themselves were reducing exposure near the highs.
The August 21 print will test whether ASP Isotopes can demonstrate the revenue inflection that justifies a $13 analyst target against a stock trading at $3.86, or whether the short sellers who have built a near-record position in the float are correct that execution remains too far behind the narrative.
See the live data behind this article on ORTEX.
Open ASPI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
